Toronto, ON – Cannabis Growth Opportunity Corporation (“CGOC”, or the “Company”) (CSE: CGOC), a cannabis focused investment corporation with both public and private cannabis holdings, provides an update on Jushi Inc. (“Jushi”), one of its private holdings.
Jushi announced the acquisition of Medicinal Excellence in Neurological Disorders, LLC (“MEND“). MEND is a Buffalo, New York-based cannabinoid research company focused on the development of physician-formulated cannabinoid products, together with proprietary delivery devices and administration protocols.
Contemporaneously with Jushi’s acquisition of MEND, Dr. Laszlo Mechtler, MD, FAAN, FASN, a world-renowned expert in the therapeutic potential of cannabinoids and related research, has joined Jushi as its Medical Director and will lead the Company’s hemp-derived CBD product formulation and development efforts, clinical research and medical advocacy in New York. Dr. Mechtler will remain based in Buffalo, where he serves as Chief of Neuro-Oncology at the Roswell Park Cancer Institute, a Professor of Neurology and Neuro-Oncology at the State University of New York at Buffalo, Medical Director of the DENT Neurologic Institute, Director of the Headache/Neuro-Oncology Center at DENT and Director of the DENT Cannabis Clinic.
Jushi is a Florida-based company focused on developing high quality products across the cannabinoid ecosystem. The company has partnered with licensed operators in several U.S. states and plans to launch a global medical cannabis division based on the MEND brand.
CGOC is an investment corporation that offers unique global exposure to the emerging global cannabis sector. CGOC’s main objective is to provide shareholders long-term total return through its actively managed portfolio of securities, both public and private, operating in, or that derive a portion of their revenue or earnings from products or services related to the cannabis industry.
For further information please contact:
Cannabis Growth Opportunity Corporation